Melatonin

Melatonin

10 mg

10 mg

180 Quick Dissolve Tablets ( SKU: 9286U )

Benefits

  • Quick-dissolve tablets have fast melatonin absorption*
  • Derived from non-animal sources 
  • A singular powerful quick-dissolve tablet is optimal for those who benefit from higher amounts of melatonin (10–20 mg)
  • Refreshing, natural peppermint flavor
  • Non-habit forming

Feature Summary

Sleep is a vital part of health and many of us are not getting enough. Occasional sleeplessness affects about one third of adults in the United States1 and up to half of older adults.2 Changes in sleeping patterns are largely reflective of our circadian rhythms, which are guided by the pineal hormone, melatonin. Melatonin is known to decline as we age, which accounts for a number of the sleep changes we see throughout life. Additionally, jet lag and shift work can significantly alter circadian rhythms and thus melatonin secretion.3,4,5

 

Melatonin helps increase the total sleep time (aspect of sleep quality) in people suffering from occasional sleep restriction or altered sleep schedule (e.g., shift-work and jet lag),6,7 supporting alertness during waking hours and helping to maintain a healthy sleep-wake cycle.*8,9 Occasional sleep deficiency can lead to less than optimal health10 and it is so important to be aware of just how important it is to maintain normal melatonin levels to support sleep quality.*

Supplement Facts:

Allergens:

Contains no artificial colors, preservatives, or sweeteners; no starch, sugar, wheat, gluten, yeast, soy, egg, fish, shellfish, salt, tree nuts, or GMOs. Suitable for vegetarians.

Dosage:

Suggested Usage: Chew or dissolve 1 tablet at bedtime in the mouth before swallowing or as directed by a health care professional. For use beyond 4 weeks, consult a health care professional.

Contraindications

Consumption with alcohol, other medications or natural health products with sedative properties is not recommended. 

Drug Interactions

Melatonin may impair glucose utilization and increase insulin resistance in diabetic patients. However, the clinical significance of this effect on diabetics is unknown.11 Contraceptive drugs can increase endogenous melatonin levels. Theoretically, this may increase the effects and adverse effects of oral melatonin use.12 Fluvoxamine significantly inhibits the elimination of melatonin,13 which some researchers believe could be helpful in the treatment of refractive insomnia.14 However, this interaction may also cause excessive unwanted drowsiness and other adverse effects. Melatonin production and release may be inhibited by beta-blockers15 and non-steroidal anti-inflammatory drugs.16

  1. Roth T. (2005). The Journal of Clinical Psychiatry, 66(Suppl 9), 10-43. 
  2. Brewster, G.S., Riegel, B., & Gehrman, P. R. (2018). Sleep Medicine Clinics, 13(1), 13-9.
  3. Karasek, M., & Winczyk, K. (2006). Journal of Physiology and Pharmacology, 57(Suppl 5), 19-39.
  4. Zawilska, J.B., Skene, D.J., & Arendt, J. (2009). Pharmacological Reports, 61(3), 383-410.
  5. Alternative Medicine Review. (2005). Melatonin Monograph. Alternative Medicine Review, 10(4), 326-36.
  6. Kunz, D., Mahlberg, R., Muller, C., et al. (2004). Journal of Clinical Endocrinology and Metabolism, 89(1), 128-34.
  7. Bjorvatn, B., & Pallesen, S. (2009). Sleep Medicine Reviews, 13(1), 47-60.
  8. Wade, A.G., Ford, I., Crawford, G., et al. (2007). Current Medical Research and Opinion, 23(10), 2597-605.
  9. Wade, A.G., Ford, I., Crawford, G., et al. (2010). BMC Medicine, 8, 51.
  10. Litinski, M., Scheer, F.A., Shea, S.A. (2009). Sleep Medicine Clinics, 4(2), 143-63.
  11. Cagnacci, A., Arangino, S., Renzi, A., et al. Clinical Endocrinology, 54(3), 339-46.
  12. Wright Jr, K.P., Myers, B.L., Plenzler, S.C., et al. (2000). Brain Research, 873(2), 310-7.
  13. Hartter, S., Grozinger, M., Weigmann, H., et al. (2000). Clinical Pharmacology & Therapeutics, 67(1), 1-6.
  14. Grozinger, M., Hartter, S., Wang, X., et al. (2000). Archives of General Psychiatry, 57(8), 812-3.
  15. Stoschitzky, K., Sakotnik, A., Lercher, P., et al. (1999). European Journal of Clinical Pharmacology, 55, 111-5.
  16. Murphy, P.J., Myers, B.L., Badia, P. (1996). Physiology & Behavior, 59, 133-9.